Regeneron reported fourth-quarter adjusted earnings of $11.44 per share, surpassing the Zacks Consensus Estimate of $10.56 by 8.3%. This marked a year-over-year decline from $12.07 per share in Q4 of the prior year, reflecting investment in R&D and one-time charges. The company also announced revenues that exceeded analyst forecasts, driven by strong sales across its immunology and ophthalmology franchises.

Dupixent continued to outpace expectations, with global sales increasing 45% year-over-year. In the U.S., prescriptions grew 40% sequentially, reflecting expanded label approvals for atopic dermatitis and asthma. Management highlighted a doubling of new patient starts in Europe and Japan, underscoring the drug’s broadening market penetration and its role as Regeneron’s fastest-growing product line.

Ahead of the earnings release, several top-ranked analysts raised their full-year EPS forecasts by an average of $0.75, citing strong Dupixent momentum and anticipated launches in oncology. Regeneron provided 2024 guidance for organic revenue growth of 12%–14% and non-GAAP EPS in the range of $52.00 to $54.00, reflecting continued investment in pipeline assets, including its Phase III bispecific antibody programs.

Investors are focused on Regeneron’s ability to sustain high single-digit revenue growth outside Dupixent while advancing its cardiovascular and ophthalmology candidates. The company’s robust free cash flow generation—projected at over $5 billion for the year—supports ongoing share repurchases and dividend initiatives. Market participants will closely watch clinical readouts for the anti-IL-22 and anti-VEGF programs, which could drive the next phase of valuation uplift.